SINDAS more data.

Bearing in mind the overall oligodata for consolidative local therapy for oligometastatic non-small cell lung cancer (NSCLC), the Chinese prospective phase 3 SINDAS trial presented last week in abstract form was big progress. 133 patients receiving upfront EGFR-TKI for EGFR-mutated NSCLC with ≤5 mets and 0 brain mets were randomized across 5 centers to +/- upfront ablative radiation to all sites of disease in conjunction with initiation of systemic therapy. At time of analysis, the primary endpoint of median progression-free survival  was significantly improved with radiation from >12 → >20 months. Much more interesting was the secondary endpoint of median overall survival that was significantly improved from >17 → >25 months. TBL: While we await details of the full pub, this preliminary reporting adds significant fuel to the excitement of upfront consolidative therapy for oligometastatic EGFR-mutated NSCLC—even in the era of TKIs. | Wang, ASCO 2020